M2 EQUITYBITES-June 26, 2012-Microcyn-Based Drugs To Be Developed By AmDerma And Oculus(C)2012 M2 COMMUNICATIONS http://www.
AmDerma Pharmaceuticals, the parent company of Quinnova Pharmaceuticals Inc, and Oculus Innovative Sciences Inc, a commercial healthcare company that designs, produces and markets tissue care products based upon the Microcyn Technology platform, have signed a multi-country agreement to develop and market Microcyn technology drug compounds for dermatological conditions, it has been reported today.
M2 PHARMA-June 26, 2012-Microcyn-Based Drugs To Be Developed By AmDerma
And Oculus(C)2012 M2 COMMUNICATIONS
According to the company, a subsidiary of AmDerma
LLC, the nonsteroidal prescription topical treatments are for skin disorders and wound care.
A wholly owned subsidiary of AmDerma
, LLC, Quinnova Pharmaceuticals, Inc.
Quinnova has become an independent affiliate of Amneal Enterprises via its acquisition by AmDerma
now carries Amderma
Cellular Renewal Emulsion, an item billed as a collagen-boosting complex that helps diminish the appearance of fine lines and wrinkles.
is now carrying Amderma Cellular Renewal Emulsion on its shelves.
Amderma Cellular Renewal Emulsion is now being offered at CVS stores for $29.
Pharmaceuticals, LLC, an Amneal alliance member, will pay Oculus $500,000 as a non-refundable initial payment as an option to license the Microcyn technology for an acne new drug application, with the option expiring June 30, 2011.
Newtown, PA, as an independent affiliate of Amneal Enterprises, LLC via its acquisition by AmDerma